Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.8000+0.0128 (+1.63%)
At close: 04:00PM EDT
0.8300 +0.03 (+3.75%)
After hours: 04:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close0.7872
Open0.8000
Bid0.8150 x 800
Ask0.8199 x 1100
Day's Range0.7776 - 0.8300
52 Week Range0.6800 - 19.8700
Volume188,933
Avg. Volume350,266
Market Cap26.257M
Beta (5Y Monthly)1.94
PE Ratio (TTM)N/A
EPS (TTM)-3.2550
Earnings DateAug 08, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SPRO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Spero Therapeutics, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • Skift

    The Women Who Shaped Short-Term Rental History

    The dudes got all the headlines and — let’s face it — because of ingrained sexism and the traditional old boys’ networks, they took an inordinate share of the top jobs, but there were many talented women leaders and entrepreneurs who likewise shaped the history and trajectory of the global short-term rental industry. These women […]

  • Reuters

    UPDATE 1-U.S. FDA declines to approve Spero's urinary tract infection drug

    The U.S. Food and Drug Administration (FDA) declined to approve Spero Therapeutics Inc's oral antibiotic drug for the treatment of patients with complicated urinary tract infections, the company said on Monday. In the complete response letter, the health regulator concluded that Spero's late-stage study testing the drug was insufficient and an additional study would be required, the drugmaker said. Spero had sought approval for its most advanced drug candidate, tebipenem, to treat the infections, including a type of kidney inflammation called pyelonephritis in adult patients with limited oral treatment options.

  • GlobeNewswire

    Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application

    CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) seeking approval for tebipenem HBr oral tablets for treatment of adult patients with complicated urinary tract infection (cUTI), including pyelonephritis. The FDA had set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022. In th

Advertisement
Advertisement